amylin receptor

Amylin agonist 1 (Example 239a) is an agonist of amylin receptor 3 (AMY3R) with an EC50 of 6.17 nM for stimulating cellular cAMP production. It also acts as an agonist of the calcitonin receptor (CTR) with an EC50 of 8.58 nM. Amylin agonist 1 is applicable for research in type 2 diabetes and obesity.

AC 187 Acetate is a potent antagonist of amylin receptor .AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors.

AC 187 TFA, a potent and orally active amylin receptor antagonist, exhibits an IC50 of 0.48 nM and a Ki of 0.275 nM. It demonstrates greater selectivity for the amylin receptor over calcitonin and CGRP receptors and has been shown to possess neuroprotective effects [1] [2].

Cagrilintide is a long-acting amylin analogue acting as a dual agonist of the amylin receptor and calcitonin receptor, reducing body weight and food intake for obesity research.

Amylin, amide, rat acetate is a potent and high affinity ligand of AMY1 and AMY3 receptors and variably of AMY2 receptors.

Calcitonin (8-32), salmon is a highly selective amylin receptor antagonist. Calcitonin, a hormone involved in calcium and phosphorus metabolism, is primarily produced by the parafollicular or C cells in the mammalian thyroid gland and is a 32 amino acid peptide cleaved from a larger prohormone.

cAC 253 acetate (TP2135 Free base) is an amylin antagonist. cAC 253 acetate inhibits 125I-adrenomedullin binding, with an IC50 of 25 nM.

Eloralintide (LY 3841136) sodium is an AMYR agonist that shows promise for research in type 2 diabetes and obesity.

Cyclic AC253 is an amylin receptor antagonist with an IC50 of 0.3 μM. It offers neuroprotective effects against Aβ toxicity and mitigates Aβ-induced impairments in hippocampal long-term potentiation. Additionally, Cyclic AC253 is capable of penetrating the blood-brain barrier.

Lenbelintide is a dual amylin/calcitonin receptor agonist, useful in studies related to obesity.

NN1213 (Peptide 21) is a long-acting human amylin peptide analogue that functions as a selective amylin receptor agonist. It has an EC50 of 0.177 nM for hAMY3R and 0.262 nM for rAMY3R. In both rat and dog models, NN1213 significantly reduces appetite and is utilized in anti-obesity research.

NN1213 acetate (Peptide 21) is a long-acting human amylin peptide analog, functioning as a selective amylin receptor agonist with EC50 values of 0.177 nM for hAMY3R and 0.262 nM for rAMY3R. In rat and dog models, NN1213 acetate significantly reduces appetite and is applicable for anti-obesity research.

Davalintide is an Amylin-mimetic peptide known for its high potency and extended action. It is a highly effective agonist of the amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM), and calcitonin gene-related peptide receptor [CGRP receptor] (IC50 = 3.1 nM). Davalintide demonstrates greater efficacy than Amylin in cyclic adenosine monophosphate production through calcitonin receptor activation (EC50 = 1.4 nM). It modulates blood glucose and body weight through mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide is utilized in research related to anti-obesity and antidiabetic treatments.

Amylin (8-37), human, derived from human Amylin, possesses direct vasodilator effects in isolated mesenteric resistance arteries of rats. Human Amylin is a small pancreatic β-cell hormone that forms aggregates in the absence of insulin and is a key pathological feature of type II diabetes mellitus.

Pramlintide, a polypeptide analog of human amylin, is an antidiabetic agent with antineoplastic properties in colorectal cancer.

Pramlintide TFA, a polypeptide analogue of human amylin and an antidiabetic agent, exhibits antineoplastic properties in colorectal cancer [1].

Amylin, amide, human TFA, a 37-amino acid polypeptide, functions as a pancreatic hormone cosecreted with insulin, playing distinct roles in metabolism and glucose homeostasis by regulating blood sugar through inhibiting glucagon secretion, delaying gastric emptying, and promoting satiety [1].

Amylin (IAPP), feline TFA, a 37-amino acid polypeptide derived from felines, is a principal secretion product of the pancreatic islets' β-cells. This regulatory peptide notably inhibits the secretion of insulin and glucagon [1].

Amylin (8-37) (human) (hIAPP (8-37)) is the 8-37 fragment of human islet amyloid polypeptide (IAPP) and exhibits a duplex folding with a hairpin structure [1].

Amylin (1-37), human acetate (hIAPP (1-37), acetate), a peptide hormone containing 37 amino acids secreted by the pancreas in conjunction with insulin, inhibits glucagon secretion and produces satiety during glucose homeostasis, and is a major component of amyloid deposits in the pancreas of patients with type 2 diabetes.

Acetyl-Amylin (8-37) (human) is a specific amylin antagonist [1].

NI-203 is a monoclonal antibody inhibitor that targets amylin and shows potential for research in type 2 diabetes.

Amylin, amide, human acetate (122384-88-7, free) is a 37-amino acid peptide hormone co-secreted with insulin. It inhibits glucagon secretion and delays gastric emptying, playing a crucial role in metabolism and maintaining glucose homeostasis.

Amylin, amide, human is a 37-amino acid peptide hormone co-secreted with insulin to regulate postprandial glucose levels, reducing glucagon secretion and delays gastric emptying. DAP Amide's tendency to aggregate into amyloid fibrils is associated with pancreatic β-cell damage in type 2 diabetes.